Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/53000
Title: Anti-Albuminuric Effects of the Angiotensin AT1 Receptor Blocker Telmisartan in Hypertensive Patients
Authors: Rodriguez-Perez, Jose C. 
Garcia-Bello, Miguel A.
Anabitarte-Prieto, Aranzazu
Companioni, Osmel
Novoa-Mogollon, Francisco J.
Suarez-Ortega, Saturnino 
Plaza-Toledano, Celia
Rodriguez-Esparragon, Francisco 
Keywords: Randomized Controlled-Trial
Blood-Pressure
Overt Nephropathy
High-Risk
Prevention, et al
Issue Date: 2011
Publisher: 1064-1963
Journal: Clinical and Experimental Hypertension 
Abstract: We evaluated the anti-hypertensive and anti-albuminuric effect of the angiotensin receptor blocker telmisartan alone and in combination with torasemide and amlodipine. Patients were hypertensive, both diabetics and non-diabetics with persistent microalbuminuria. Our primary endpoint was a change in microalbuminuria levels, while the secondary endpoints were changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), serum creatinine levels, and glomerular filtration rate. After the 16-week treatment period, the patients significantly reduced microalbuminuria levels (76.4 +/- 52.4 mu g/min; p < 0.001), SBP (16.4 +/- 8.7 mmHg; p < 0.001) and DBP (17.7 +/- 5.9 mmHg; p < 0.001). Both diabetics and non-diabetics showed an identical pattern of significance with respect to the whole population. Systolic blood pressure, DBP, and microalbuminuria were significantly reduced as a consequence of therapy, both in diabetics and non-diabetics.
URI: http://hdl.handle.net/10553/53000
ISSN: 1064-1963
DOI: 10.3109/10641963.2011.561900
Source: Clinical And Experimental Hypertension[ISSN 1064-1963],v. 33 (8), p. 506-510
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

2
checked on Jul 3, 2022

WEB OF SCIENCETM
Citations

2
checked on Jul 3, 2022

Page view(s)

18
checked on Jul 2, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.